202 related articles for article (PubMed ID: 36894639)
1. Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.
Wu Y; Zhou L; Zou Y; Zhang Y; Zhang M; Xu L; Zheng L; He W; Yu K; Li T; Zhang X; Chen Z; Zhang R; Zhou P; Zhang N; Zheng L; Kang T
Nat Cancer; 2023 Mar; 4(3):382-400. PubMed ID: 36894639
[TBL] [Abstract][Full Text] [Related]
2. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling.
Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I
Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543
[TBL] [Abstract][Full Text] [Related]
3. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Garcia-Diaz A; Shin DS; Moreno BH; Saco J; Escuin-Ordinas H; Rodriguez GA; Zaretsky JM; Sun L; Hugo W; Wang X; Parisi G; Saus CP; Torrejon DY; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Damoiseaux R; Lo RS; Ribas A
Cell Rep; 2017 May; 19(6):1189-1201. PubMed ID: 28494868
[TBL] [Abstract][Full Text] [Related]
4. KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1.
Yoshino H; Sato Y; Nakano M
Curr Issues Mol Biol; 2021 May; 43(1):153-162. PubMed ID: 34069326
[TBL] [Abstract][Full Text] [Related]
5. SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis.
Gao K; Shi Q; Gu Y; Yang W; He Y; Lv Z; Ding Y; Cao W; Wang C; Wan X
Cell Death Differ; 2023 Feb; 30(2):475-487. PubMed ID: 36481790
[TBL] [Abstract][Full Text] [Related]
6. IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell.
Shao L; Hou W; Scharping NE; Vendetti FP; Srivastava R; Roy CN; Menk AV; Wang Y; Chauvin JM; Karukonda P; Thorne SH; Hornung V; Zarour HM; Bakkenist CJ; Delgoffe GM; Sarkar SN
Cancer Immunol Res; 2019 Aug; 7(8):1258-1266. PubMed ID: 31239318
[TBL] [Abstract][Full Text] [Related]
7. Triptolide reduces PD-L1 through the EGFR and IFN-γ/IRF1 dual signaling pathways.
Xie Y; Ding J; Gao J; Zhang J; Cen S; Zhou J
Int Immunopharmacol; 2023 May; 118():109993. PubMed ID: 36931170
[TBL] [Abstract][Full Text] [Related]
8. Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells.
Ebine K; Kumar K; Pham TN; Shields MA; Collier KA; Shang M; DeCant BT; Urrutia R; Hwang RF; Grimaldo S; Principe DR; Grippo PJ; Bentrem DJ; Munshi HG
Sci Rep; 2018 Sep; 8(1):13225. PubMed ID: 30185888
[TBL] [Abstract][Full Text] [Related]
9. Identification of STXBP6-IRF1 positive feedback loop in regulation of PD-L1 in cancer.
Liu Y; Huang Z; Wei Y; Zhang M; Li X; Yang S; Wang H
Cancer Immunol Immunother; 2021 Feb; 70(2):275-287. PubMed ID: 32700091
[TBL] [Abstract][Full Text] [Related]
10. Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling.
Chen Q; Zhuang S; Hong Y; Yang L; Guo P; Mo P; Peng K; Li W; Xiao N; Yu C
Oncogene; 2022 Mar; 41(10):1421-1433. PubMed ID: 35027670
[TBL] [Abstract][Full Text] [Related]
11. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
12. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
13. p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
Liu J; He D; Cheng L; Huang C; Zhang Y; Rao X; Kong Y; Li C; Zhang Z; Liu J; Jones K; Napier D; Lee EY; Wang C; Liu X
Oncogene; 2020 May; 39(19):3939-3951. PubMed ID: 32203167
[TBL] [Abstract][Full Text] [Related]
14. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
[No Abstract] [Full Text] [Related]
15. Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy.
Liang J; Wang L; Wang C; Shen J; Su B; Marisetty AL; Fang D; Kassab C; Jeong KJ; Zhao W; Lu Y; Jain AK; Zhou Z; Liang H; Sun SC; Lu C; Xu ZX; Yu Q; Shao S; Chen X; Gao M; Claret FX; Ding Z; Chen J; Chen P; Barton MC; Peng G; Mills GB; Heimberger AB
Cancer Immunol Res; 2020 Jul; 8(7):952-965. PubMed ID: 32265228
[TBL] [Abstract][Full Text] [Related]
16. Cancer Differentiation Inducer Chlorogenic Acid Suppresses PD-L1 Expression and Boosts Antitumor Immunity of PD-1 Antibody.
Li R; Zhan Y; Ding X; Cui J; Han Y; Zhang J; Zhang J; Li W; Wang L; Jiang J
Int J Biol Sci; 2024; 20(1):61-77. PubMed ID: 38164171
[TBL] [Abstract][Full Text] [Related]
17. Analysis of programmed death-ligand 1 expression in primary normal human dermal fibroblasts after DNA damage.
Hagiwara Y; Sato H; Permata TBM; Niimi A; Yamauchi M; Oike T; Nakano T; Shibata A
Hum Immunol; 2018 Aug; 79(8):627-631. PubMed ID: 29859207
[TBL] [Abstract][Full Text] [Related]
18. Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer.
Zhou Y; Liang Z; Xia Y; Li S; Liang J; Hu Z; Tang C; Zhao Q; Gong Q; Ouyang Y
Chem Biol Interact; 2023 Jan; 369():110260. PubMed ID: 36414028
[TBL] [Abstract][Full Text] [Related]
19. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
20. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy.
Gao Y; Nihira NT; Bu X; Chu C; Zhang J; Kolodziejczyk A; Fan Y; Chan NT; Ma L; Liu J; Wang D; Dai X; Liu H; Ono M; Nakanishi A; Inuzuka H; North BJ; Huang YH; Sharma S; Geng Y; Xu W; Liu XS; Li L; Miki Y; Sicinski P; Freeman GJ; Wei W
Nat Cell Biol; 2020 Sep; 22(9):1064-1075. PubMed ID: 32839551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
